Abstract Number: 1572 • 2013 ACR/ARHP Annual Meeting
High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease
Background/Purpose: Type I interferon (IFN-I) is elevated in many patients with SLE and is associated with more severe disease. However, the relationship between elevated levels…Abstract Number: 1573 • 2013 ACR/ARHP Annual Meeting
Longer Duration Of B Cell Depletion In Patients With Systemic Lupus Erythematosus Is Associated With a Better Outcome
Background/Purpose: We were alerted to the possibility of very long term B cell depletion (BCD) in Systemic Lupus Erythematosus (SLE) by a patient treated with…Abstract Number: 1574 • 2013 ACR/ARHP Annual Meeting
Favorable Clinical Response To Belimumab At Three Months
Background/Purpose: Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the…Abstract Number: 1575 • 2013 ACR/ARHP Annual Meeting
Identification Of Novel Distinct Autoantigen Clusters Reflecting The Heterogeneity Of Systemic Lupus Erythematosus
Background/Purpose: Diagnosis of systemic lupus erythematosus (SLE) is based on a combination of clinical findings and laboratory evidence such as anti-nuclear autoantibodies (ANA), anti-Smith and…Abstract Number: 1576 • 2013 ACR/ARHP Annual Meeting
Type I Interferon-Mediated Skewing Of The Serotonin Synthesis In Systemic Lupus Erythematosus Is Associated To Cardiovascular Disease
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by increased expression of type I interferons (IFNs). Indoleamine 2,3-dioxygenase (IDO), a type I…Abstract Number: 1577 • 2013 ACR/ARHP Annual Meeting
Comparison Of Clinical and Serological Manifestations Among Juvenile-, Adult-, and Late-Onset Systemic Lupus Erythematosus Patients In Korea
Background/Purpose: Up to 30‑40% of patients with systemic lupus erythematosus (SLE) experience their onset prior to adulthood or at over 50 years of age. Patients…Abstract Number: 1578 • 2013 ACR/ARHP Annual Meeting
Decreased Sensitivity Of a Commercial Anti-dsDNA Assay In Patients With Moderately To Severely Active Systemic Lupus Erythematosus
Background/Purpose: Anti-dsDNA autoantibodies are highly specific for SLE. Anti-dsDNA positivity is an important eligibility criterion in many SLE studies, and decreases in anti-dsDNA levels are…Abstract Number: 1579 • 2013 ACR/ARHP Annual Meeting
Novel Risk Factors For Thrombotic Thrombocytopenic Purpura In Systemic Lupus Erythematosus patients
Background/Purpose: Thrombotic thrombocytopenic purpura (TTP) is an uncommon disease characterized by thrombocytopenia and microangiopathic hemolytic anemia and, in some cases, fever, neurologic and/or renal abnormalities.…Abstract Number: 1580 • 2013 ACR/ARHP Annual Meeting
Drug-Resistant Bloodstream Infections In Systemic Lupus Erythematosus Patients: A Clinical Perspective
Background/Purpose: Infections are an important cause of mortality and morbidity in Systemic Lupus Erythematosus (SLE) patients. Different risk factors have been described for the development…Abstract Number: 1581 • 2013 ACR/ARHP Annual Meeting
Lipid Lowering Medication Use Is Associated With Reduced Muscle Strength In Systemic Lupus Erythematosus
Background/Purpose: Premature atherosclerotic coronary artery disease is a major source of morbidity for women with systemic lupus erythematosus (SLE). Lipid lowering medications (LLM) are among…Abstract Number: 1541 • 2013 ACR/ARHP Annual Meeting
Spinal Mobility Gets Impaired In a Fixed Order In Patients With Ankylosing Spondylitis: 12-Year OASIS Results
Background/Purpose: Spinal mobility is impaired in patients with ankylosing spondylitis (AS) compared to normal subjects. However, the extent of impairment and the relative contribution of…Abstract Number: 1542 • 2013 ACR/ARHP Annual Meeting
Regular Exercise Is Associated With Better Functional Outcomes In Ankylosing Spondylitis
Background/Purpose: Exercise and physical therapy are the cornerstones of non-pharmacologic therapy in Ankylosing Spondylitis. The long-term association of exercise on function has not been evaluated.…Abstract Number: 1543 • 2013 ACR/ARHP Annual Meeting
Patients With Ankylosing Spondylitis Are Substantially Undertreated For Hypertension and Hypercholesterolemia
Background/Purpose: Patients with ankylosing spondylitis (AS) have a decreased life expectancy due to an increased cardiovascular (CV) risk. The general inflammatory process is held responsible…Abstract Number: 1544 • 2013 ACR/ARHP Annual Meeting
Good Agreement Between The Ankylosing Spondylitis Disease Activity Scores Based On C-Reactive Protein and Erythrocyte Sedimentation Rate
Background/Purpose: Recently, ASDAS has been developed as a disease activity measuring tool for ankylosing spondylitis (AS), using a similar methodology to that used for the…Abstract Number: 1545 • 2013 ACR/ARHP Annual Meeting
Serum Periostin: a New Marker Of Local Bone Formation In Early Inflammatory Back Pain: results From The DESIR Cohort
Background/Purpose: Periostin is a secreted, homodimeric protein that is synthesized by mesenchymal cells of the periosteum, which is involved in osteoblast homeostasis of the periosteum…